Aquila Capital

EDP ​​is a global energy company in value creation, innovation and sustainability. They include in their cultural values and commitments regarding their customers, society, and environment. Their vision to be an integrated energy company, a leader in value creation in the markets where they can make a difference is shared by the universe of EDP employees, spread across different continents and countries, a diversity that enriches us and brings us together in the respect for the different cultures of the markets where they operate. They are among the major European operators in the energy sector; they are one of the largest energy operators of the Iberian Peninsula, the largest Portuguese industrial group and the 3rd largest producer of wind energy. Besides the electricity sector - generation, distribution, and trading - they also have a significant presence in the gas sector of the Iberian Peninsula. They integrate the Dow Jones Sustainability Indexes (World and STOXX), the world's most demanding ranking, that distinguishes the best-performing companies on issues related to transparency, sustainability, and excellence in economic management and social environment. EDP was founded in 1976 and is headquartered in Lisboa, Portugal.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company employs advanced antibody engineering technology to develop treatments for rare autoimmune conditions. Its notable product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address unmet medical needs in the field of immunology.